Pelareorep in Early-Stage HR+/HER2- Breast Cancer

In 2019, more than 3.7 million people in the US were living with breast cancer1. Building on the success of previous studies in which patients saw increased PD-L1 expression following pelareorep treatment, Oncolytics’ AWARE-1 clinical trial was designed to confirm pelareorep’s mechanism of action and examine its potential to synergize with immune checkpoint inhibitors using biomarker measurements such as CelTIL score, T cell infiltration and PD-L1 expression.

For additional details about this study, please visit the AWARE-1 clinical trial page.

AWARE-1 Publications

Learn more about pelareorep’s potential to remodel the tumor microenvironment by enabling the influx of CD8+ and memory T cells into the tumor and training them to fight cancer.

AWARE-1 News

For the latest updates on the AWARE-1 trial, click the link below.

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.